Anti-Human HLA-DQB1 Reference Antibody (DQB1-FL8, RUO) (HM817016)

Name: Anti-Human HLA-DQB1 Reference Antibody (DQB1-FL8, RUO)
Brand: abinScience
SKU: HM817016
Price: 326 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HM817016
Description	Anti-Human HLA-DQB1 Antibody (DQB1-FL8) (HM817016) is a research-grade recombinant antibody targeting HLA-DQB. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG1
Expression system	Mammalian cells
Clonality	Monoclonal
Target	HLA-DQB, MHC class II antigen DQB1, HLA-DQB1, HLA class II histocompatibility antigen, DQ beta 1 chain
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P01920
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	DQB1-FL8, LG11
Background	HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) is a ~29 kDa protein. Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components.
Note	For research use only. Not suitable for clinical or therapeutic use.